Hiển thị tất cả

Podcast của Tạp chí Y khoa Úc: COVID-19 ở trẻ em

Phó giáo sư Nigel Crawford của MVEC và Tiến sĩ Laila Ibrahim, bác sĩ nhi khoa và nhà nghiên cứu tại Bệnh viện Nhi đồng Hoàng gia đã giới thiệu về ấn bản mới nhất của tạp chí Medical Journal of Australia podcast.

Trong podcast này, Nigel và Laila thảo luận về COVID-19 ở trẻ em, cùng với nghiên cứu đồng tác giả của họ tập trung vào việc kiểm tra các đặc điểm dịch tễ học và lâm sàng của trẻ em dương tính với SARS‐CoV‐2 ở Úc trong năm 2020.

Bạn có thể nghe podcast tại đây:
MJA Podcast: Tập 33: COVID-19 ở trẻ em, với Tiến sĩ Laila Ibrahim và Tiến sĩ Nigel Crawford

qua Alice đen

ABC News: Why Delta COVID-19 variant could put younger people at risk of deadly cardiac complications

The COVID-19 Delta variant which is now subject of the current outbreaks in NSW, QLD and Victoria, has been linked to an increase in cases of cardiac complications in younger people. Though data is still emerging on how common the cardiac side effects are with the Delta variant, myocarditis has also been reported as a very rare side effect of mRNA COVID-19 vaccines (including Pfizer and Moderna) by the Australian Technical Advisory Group on Immunisation (ATAGI) .

According to a US study, while vaccine associated myocarditis and an associated condition, pericarditis (inflammation of the lining around the heart), could be serious, the likelihood of this occurring is low and most cases are reported to resolve quickly. Further to this, the study found that young people were around six times more likely to develop myocarditis from COVID than Pfizer, reiterating that the benefits of vaccination outweigh the risk of adverse effects from COVID-19, including for myocarditis.

To read the article in full please click on the link below:
ABC: Why Delta COVID-19 variant could put younger people at risk of deadly cardiac complications

qua Alice đen

TGA grants provisional approval for the Moderna COVID-19 vaccine (Spikevax) Elasomeran

We have updated our Moderna COVID-19 vaccination page to reflect the announcement by the Australian Technical Advisory Group on Immunisation (ATAGI) regarding the use of Moderna's COVID-19 vaccine.

On August 9 2021, The Therapeutic Goods Administration (TGA) granted provisional approval to Moderna Australia Pty Ltd for its COVID-19 vaccine—Spikevax (elasomeran).

To find out more information, please refer to our dedicated MVEC Moderna COVID-19 vaccination page in the link below.
MVEC Moderna COVID-19 vaccination page

qua Alice đen

Inside Aesthetics podcast featuring A/Prof Nigel Crawford

Associate Professor Nigel Crawford is interviewed by Dr Jake Sloane (cosmetic doctor and international injectables trainer) and David Segal (a multi-clinic owner and aesthetic entrepreneur) on their Inside Aesthetics podcast. In this episode, Nigel discusses the current vaccination landscape including vaccine safety, risk-benefit analysis, and  COVID-19 vaccination in pregnancy.

Bạn có thể nghe podcast tại đây:
Inside Aesthetics Podcast featuring Associate Professor Nigel Crawford

qua Alice đen

Updated MVEC reference page: Myocarditis and pericarditis following COVID-19 mRNA vaccines

We have updated our myocarditis and pericarditis following COVID-19 vaccines page to reflect the guidance by the Australian Technical Advisory Group on Immunisation (ATAGI) and the Cardiac Society of Australia and New Zealand (CSANZ).

ATAGI and CSANZ emphasise that the overwhelming benefits of vaccination in protecting against COVID-19 greatly outweigh the rare risk of these conditions, and Comirnaty (Pfizer mRNA vaccine) continues to be recommended for all people ≥ 16 years of age who do not have any contraindications to the vaccine, in those aged 12-15 with specific medical conditions that increase their risk of severe illness from COVID-19, and in Aboriginal and Torres Strait Islanders aged 12-15.

Để tìm hiểu thêm thông tin, vui lòng tham khảo MVEC viêm cơ tim và viêm màng ngoài tim chuyên dụng của chúng tôi sau trang vắc xin COVID-19 trong liên kết bên dưới.
MVEC myocarditis and pericarditis following COVID-19 vaccines page

qua Alice đen

ATAGI statement on the use of a different COVID-19 vaccine as the second dose

The Australian Technical Advisory Group on Immunisation (ATAGI) has released clinical guidance on the use of a different COVID-19 vaccine as the second dose.

The advice recommends to use the same COVID-19 vaccine for the 2 doses of the primary vaccination course, unless there are specific medical reasons not to do so, or the same vaccine brand is not available in Australia.

The ATAGI advice explains:
• The medical contraindications and serious vaccine-attributable adverse events after
dose 1 of a COVID-19 vaccine that warrant using an alternative vaccine brand for dose 2
• The medical conditions that mean that Comirnaty is recommended over COVID-19
Vaccine AstraZeneca
• The recommendations for completing the primary vaccination course for people who
have received dose 1 with a vaccine that is not available in Australia.

Để đọc toàn bộ tuyên bố, vui lòng nhấp vào liên kết bên dưới:
ATAGI statement: ATAGI clinical advice on use of a different COVID-19 vaccine as the second dose in special circumstances

For further information on COVID-19 mixed vaccine schedules refer to MVEC: COVID-19 mixed vaccine schedules. 

qua Alice đen

Change in timing for Pfizer second dose (in Victoria)

In order for more Victorians to receive their first dose of a COVID-19 vaccine, it is now recommended dose 2 of Pfizer COVID-19 vaccine (Comirnaty™) is administered 6 weeks after dose 1.

Individuals who currently have their second dose of Comirnaty™ booked do not need to reschedule their appointments.

This change only applies in Victoria.

For further information refer to the link below:

Department of Health: Change in timing for Pfizer second dose

qua Alice đen